OOIR: Observatory of International Research

Papers

(The H4-Index of Biomarker Research is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Roles of IFN-γ in tumor progression and regression: a review	502
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors	255
Metabolic reprogramming in macrophage responses	207
Biomarkers for cancer-associated fibroblasts	138
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives	115
A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)	106
miR-21: a non‐specific biomarker of all maladies	103
Recent advances in systemic therapy for hepatocellular carcinoma	91
The landscape of bispecific T cell engager in cancer treatment	85
Targeting ferroptosis in breast cancer	84
Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer	69
CAR-NK cells for cancer immunotherapy: from bench to bedside	64
Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study	63
A comprehensive comparison between camelid nanobodies and single chain variable fragments	62
Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study	61
Novel insights on targeting ferroptosis in cancer therapy	60
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion	59
Role of platelet biomarkers in inflammatory response	58
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy	55
Imaging biomarkers for evaluating tumor response: RECIST and beyond	52
Immunotherapy in endometrial cancer: rationale, practice and perspectives	50
Nanobody-based CAR-T cells for cancer immunotherapy	48
Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues	48
Alternative Polyadenylation: a new frontier in post transcriptional regulation	48
Role of DNA repair defects in predicting immunotherapy response	47

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies	47
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma	46
The biological function and clinical significance of SF3B1 mutations in cancer	45
Prolonged elevation of serum neurofilament light after concussion in male Australian football players	44
The role of estrogen receptor beta in breast cancer	44
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia	43
Cancer-associated adipocytes as immunomodulators in cancer	43
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth	42
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	42
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	40
Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment	40
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis	39
The role of ferroptosis in lung cancer	39
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	38